FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008104283> ?p ?o ?g. }

• W2008104283 endingPage "1405" @default.
• W2008104283 startingPage "1401" @default.
• W2008104283 abstract "Obesity is a substantial and increasing contributor to morbidity and mortality worldwide. Somatic and psychiatric complications allied to obesity are common. Diet, lifestyle and psychological interventions are recommended treatments, but often fail. Consequently medication interventions, and increasingly bariatric surgery, are viewed as supplementary mechanisms to manage the problem 1. Numerous pharmaceutical interventions have been devised to treat obesity 2. However, the history of orexigenic drugs has been plagued with problems. A bevy of weight loss drugs have exited the marketplace because of safety concerns – usually as a result of cardiovascular and/or psychiatric adverse events – and include fenfluramine phentermine combination (‘fen-phen’), rimonabant, and sibutramine 3. Replacing them are three new prescription agents available for oral administration for long-term use: lorcaserin 4, phentermine topiramate combination 5, and naltrexone bupropion combination 6. Are they effective? Are they safe? Let's take the 15-min challenge to sort some of these issues out. Step 1. Obtain the prescribing information from the web 4-6. Construct a table of pertinent information regarding indications, contraindications, bolded boxed warnings, dosage recommendations, drug interactions, and most commonly encountered adverse effects (incidence ≥ 5%) (Table 1). Although all of the interventions have essentially the same indication (adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults), they differ in mechanism of action, and for the combination medication products, represent the re-purposing of agents that have already been available for quite some time. Two of the products are classified as Category IV by the US Drug Enforcement Agency because of a potential of abuse, however, naltrexone bupropion combination is not (other examples of Category IV medications include benzodiazepines). All three products are contraindicated in pregnant women. The combination products have longer lists of additional contraindications, and naltrexone bupropion combination has an additional bolded boxed warning regarding suicidality (a warning that is found in the product labels of all agents that have been approved as antidepressants). Lorcaserin does not require titration but is taken twice daily. Phentermine and topiramate combination is taken once daily but requires titration. Naltrexone and bupropion combination requires both titration and twice daily dosing. Drug interactions can occur with any of these agents, with a longer list present for the combination products, especially for naltrexone bupropion combination. All of the agents have their own distinct adverse event profile. Step 2. Extract the efficacy information regarding the achievement of a ≥ 5% or 10% reduction from baseline body weight and calculate the number needed to treat (NNT) vs. placebo (Table 2). The most robust effect sizes are observed with phentermine topiramate combination, with the 95% confidence intervals of the NNT free of any overlap with those for the other products. Step 3. Extract the safety and tolerability information regarding the proportion of patients who discontinued the clinical trial(s) because of an adverse event and calculate the number needed to harm (NNH) vs. placebo. Do the same for the incidence of the most common adverse event (Table 3). Lorcaserin appears to be the best tolerated based on the NNH vs. placebo for patients discontinuing because of an adverse event, and in terms of the NNH for the adverse event most commonly observed with that agent (headache). Step 4. Compare and contrast. The concept of likelihood to be helped or harmed (LHH) can be helpful here, provided that you select a relevant harm to contrast with the anticipated benefit 7. Table 4 provides the NNT for response, NNH for discontinuation because of an adverse event, and the resultant LHH. Lorcaserin is almost 11 times more likely to result in ≥ 5% weight loss than a discontinuation because of an adverse event. LHH for these outcomes for phentermine and topiramate combination is 6, and for naltrexone and bupropion combination, almost 2. LHH values are lower (less favourable) when the bar for weight loss rises to a 10% threshold. LHH values are also lower when the calculation is made using the NNH for the most commonly encountered adverse event (Table 5). For naltrexone and bupropion combination the LHH in this instance is less than 1. Thus, one would expect to encounter the adverse event (nausea) more often than weight loss. However, this does not necessarily eliminate naltrexone and bupropion combination from further consideration if the nausea is mild, temporary, and easily managed. There are several important caveats. The data presented are from carefully conducted registration trials that enrolled subjects who fulfilled restrictive inclusion/exclusion criteria. Such patients may differ from persons encountered in routine clinical practice. Thus pragmatic clinical trials that are more generalizable will help place these weight loss agents into clinical perspective for their use in the ‘real world’. In addition, the data presented are regarding the highest approved dose for each product. Not mentioned in this mini-review is orlistat 8, a reversible inhibitor of gastrointestinal lipases, also approved for obesity management with a similar indication as for the products discussed here, and available by prescription since 1999, and now also over-the counter in lower dose strengths. The threshold of a 5% reduction in body weight is arbitrary and just a start. To achieve desired reductions in blood pressure, plasma lipids, and improvements in insulin resistance, greater weight loss will likely be important. Prior to prescribing any of these agents, attention should be paid to potential drug–drug interactions that can impact on safety and tolerability. Adoption of healthier lifestyles that include regular exercise and more wholesome diets will also be necessary to optimise the management of obesity. The author thanks Anthony Wierzbicki, Associate Editor for Cardiovascular Disease Prevention and Metabolic Diseases for the International Journal of Clinical Practice, for his helpful review and suggestions. No external funding or writing assistance was utilised in the production of this editorial. Although the average clinician may take 15 min to read the editorial and accompanying tables, the creation of this mini-review took well in excess of 15 h. In the past 36 months, Leslie Citrome has engaged in collaborative research with, or received consulting or speaking fees, from: Alexza, Alkermes, AstraZeneca, Avanir, Bristol-Myers Squibb, Eli Lilly, Forest, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, and Valeant." @default.
• W2008104283 created "2016-06-24" @default.
• W2008104283 creator A5013970045 @default.
• W2008104283 date "2014-11-24" @default.
• W2008104283 modified "2023-10-16" @default.
• W2008104283 title "Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out" @default.
• W2008104283 cites W1597838323 @default.
• W2008104283 cites W2073675444 @default.
• W2008104283 cites W2094916253 @default.
• W2008104283 cites W2746751342 @default.
• W2008104283 doi "https://doi.org/10.1111/ijcp.12587" @default.
• W2008104283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25418525" @default.
• W2008104283 hasPublicationYear "2014" @default.
• W2008104283 type Work @default.
• W2008104283 sameAs 2008104283 @default.
• W2008104283 citedByCount "10" @default.
• W2008104283 countsByYear W20081042832015 @default.
• W2008104283 countsByYear W20081042832016 @default.
• W2008104283 countsByYear W20081042832019 @default.
• W2008104283 countsByYear W20081042832021 @default.
• W2008104283 countsByYear W20081042832022 @default.
• W2008104283 crossrefType "journal-article" @default.
• W2008104283 hasAuthorship W2008104283A5013970045 @default.
• W2008104283 hasBestOaLocation W20081042831 @default.
• W2008104283 hasConcept C118552586 @default.
• W2008104283 hasConcept C126322002 @default.
• W2008104283 hasConcept C142724271 @default.
• W2008104283 hasConcept C170493617 @default.
• W2008104283 hasConcept C2776885963 @default.
• W2008104283 hasConcept C2777683783 @default.
• W2008104283 hasConcept C2777843972 @default.
• W2008104283 hasConcept C2777972943 @default.
• W2008104283 hasConcept C2778186239 @default.
• W2008104283 hasConcept C2778456266 @default.
• W2008104283 hasConcept C2779908668 @default.
• W2008104283 hasConcept C42219234 @default.
• W2008104283 hasConcept C511355011 @default.
• W2008104283 hasConcept C544821477 @default.
• W2008104283 hasConcept C71924100 @default.
• W2008104283 hasConcept C98274493 @default.
• W2008104283 hasConceptScore W2008104283C118552586 @default.
• W2008104283 hasConceptScore W2008104283C126322002 @default.
• W2008104283 hasConceptScore W2008104283C142724271 @default.
• W2008104283 hasConceptScore W2008104283C170493617 @default.
• W2008104283 hasConceptScore W2008104283C2776885963 @default.
• W2008104283 hasConceptScore W2008104283C2777683783 @default.
• W2008104283 hasConceptScore W2008104283C2777843972 @default.
• W2008104283 hasConceptScore W2008104283C2777972943 @default.
• W2008104283 hasConceptScore W2008104283C2778186239 @default.
• W2008104283 hasConceptScore W2008104283C2778456266 @default.
• W2008104283 hasConceptScore W2008104283C2779908668 @default.
• W2008104283 hasConceptScore W2008104283C42219234 @default.
• W2008104283 hasConceptScore W2008104283C511355011 @default.
• W2008104283 hasConceptScore W2008104283C544821477 @default.
• W2008104283 hasConceptScore W2008104283C71924100 @default.
• W2008104283 hasConceptScore W2008104283C98274493 @default.
• W2008104283 hasIssue "12" @default.
• W2008104283 hasLocation W20081042831 @default.
• W2008104283 hasLocation W20081042832 @default.
• W2008104283 hasOpenAccess W2008104283 @default.
• W2008104283 hasPrimaryLocation W20081042831 @default.
• W2008104283 hasRelatedWork W1963798303 @default.
• W2008104283 hasRelatedWork W2000866847 @default.
• W2008104283 hasRelatedWork W2004929929 @default.
• W2008104283 hasRelatedWork W2052977571 @default.
• W2008104283 hasRelatedWork W2071828445 @default.
• W2008104283 hasRelatedWork W2084770204 @default.
• W2008104283 hasRelatedWork W2116907077 @default.
• W2008104283 hasRelatedWork W2317290477 @default.
• W2008104283 hasRelatedWork W2590954942 @default.
• W2008104283 hasRelatedWork W4294670757 @default.
• W2008104283 hasVolume "68" @default.
• W2008104283 isParatext "false" @default.
• W2008104283 isRetracted "false" @default.
• W2008104283 magId "2008104283" @default.
• W2008104283 workType "article" @default.